期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 21, 页码 15593-15607出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00419
关键词
-
资金
- Snyder Robinson Foundation [UCF25068A04]
- NIH [NIH S10 OD021758-01A1]
- National Institutes of Health (NIH) [R01NS109640]
A spermine prodrug was developed in this study, which successfully increased intracellular spermine levels in SRS fibroblasts. Administering the prodrug in a Drosophila SRS model showed significant beneficial effects, providing a lead compound for future spermine replacement therapy experiments.
Snyder Robinson Syndrome (SRS) is a rare disease associated with a defective spermine synthase gene and low intracellular spermine levels. In this study, a spermine replacement therapy was developed using a spermine prodrug that enters cells via the polyamine transport system. The prodrug was comprised of three components: a redox-sensitive quinone trigger, a trimethyl lock (TML) aryl release mechanism, and spermine. The presence of spermine in the design facilitated uptake by the polyamine transport system. The quinone-TML motifs provided a redox-sensitive agent, which upon intracellular reduction generated a hydroquinone, which underwent intramolecular cyclization to release free spermine and a lactone byproduct. Rewardingly, most SRS fibroblasts treated with the prodrug revealed a significant increase in intracellular spermine. Administering the spermine prodrug through feeding in a Drosophila model of SRS showed significant beneficial effects. In summary, a spermine prodrug is developed and provides a lead compound for future spermine replacement therapy experiments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据